COVID-19 >>"True and Helpful" Covid Information Thread

[Anonymous]

At least the virus is becoming less lethal.

[cc]

Yes, MUCH less



WOW - The actual improvement is even FAR greater than above (which used "Totals to date from the very start)





I just calculated last 2 months only (back from the 16th as there is always a lag between cases and deaths)



Also I  took snapshots at May16 & June 16 to compare to





Canada:



June 16  = 99,450 cases &   8,213 deaths = rate was 1 death / 13 cases  (nightmare scenario) - (same rate for &  May 16)



Aug 16 to Oct 16 =  71,859 cases vs  102 deaths = 1 death per 102 cases





BC



June 16  >  it was 1 death / 16 cases (nightmare scenario) - (same rate for &  May 16)





Aug 16 to Oct 16 - 6689 cases vs 50 deaths = 1 death / 134 case

[Anonymous]

We should know by now which treatments work, even over the counter medication.

[Anonymous]

We should know by now which treatments work, even over the counter medication.

I see more helpful information posted by cc than anything Theresa Tam has said.

[Anonymous]

We should know by now which treatments work, even over the counter medication.

I see more helpful information posted by cc than anything Theresa Tam has said.

 

[Anonymous]

An inhaled nasal steroid may prevent mild symptoms from becoming serious.



RI-MUHC researchers initiate a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening



Montreal, September 16, 2020 – Steroid drugs are anti-inflammatory medicines that are used to treat a wide range of conditions, and one of them – oral or intravenous dexamethasone – was found effective in improving the survival of patients with severe COVID-19. Could other drugs from the same family show potential to treat milder cases of COVID? A team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) believes so. On September 14, 2020, they started testing the efficiency of ciclesonide, an inhaled and nasal steroid drug currently used for asthma and nasal rhinitis. Laboratory studies have already shown that treatment with ciclesonide can decrease viral replication of SARS-Cov2, the virus responsible for the disease. This placebo-controlled randomized trial will confirm if the administration of inhaled and nasal ciclesonide can reduce the severity of respiratory symptoms among mild cases of COVID-19 and potentially avoid the need for hospitalization and oxygen.

https://muhc.ca/news-and-patient-stories/research/nip-it-bud-new-study-will-attack-sars-cov2-where-it-multiplies">https://muhc.ca/news-and-patient-storie ... multiplies">https://muhc.ca/news-and-patient-stories/research/nip-it-bud-new-study-will-attack-sars-cov2-where-it-multiplies

[cc]

Good find Fash

[cc]

October 28, 2020  



The search for COVID-19 treatments: 32 clinical trials happening right now in Canada



As of Wednesday morning, there were 32 active clinical trials in Canada related to COVID-19, including efforts to stop the progression of the illness in patients with severe disease, and tests measuring how COVID-19 responds to drugs already approved for other illnesses.



Here are a just a few of the ongoing trials:



CINC424J12301 RUXCOVID: Ruxolitinib, a drug used to treat high-risk myelofibrosis, is being tested to see if it can stop the cytokine storm created when a body's response to COVID-19 kicks its immune system into overdrive.





JF-4-2020: This trial involves peginterferon-lambda, a part of the human antiviral immune response that proponents believe may have a lower risk of serious side effects than other potential COVID-19 treatments.





PROTOCOL 214094: COVID-19 patients with severe pulmonary symptoms may be eligible for this trial from pharmaceutical company GlaxoSmithKline, which uses an antibody known as Otilimab.



https://www.ctvnews.ca/health/coronavirus/the-search-for-covid-19-treatments-32-clinical-trials-happening-right-now-in-canada-1.5164404">The search for COVID-19 treatments: 32 clinical trials happening right now in Canada



20-5449: Nitric oxide – not to be confused with nitrous oxide, also known as laughing gas – is being tested in intubated COVID-19 patients to see if it inhibits the disease.



2149: Some critically ill COVID-19 patients at Sunnybrook Health Sciences Centre in Toronto are subjects in this trial, which uses anesthetic drug isoflurane.



ARBS CORONA II: Normally used to treat high blood pressure, losartan is being tested on COVID-19 patients in this trial.



CATCO: Toronto's Sunnybrook Research Institute is handling the Canadian side of the World Health Organization-backed trial of remdesivir in hospitalized COVID-19 patients.



CINC424J12301 RUXCOVID: Ruxolitinib, a drug used to treat high-risk myelofibrosis, is being tested to see if it can stop the cytokine storm created when a body's response to COVID-19 kicks its immune system into overdrive.



CIRCA-19: Tests of a cellular immunotherapy treatment are being conducted by a team from the Ottawa Health Research Institute.



COLCORONA-MHIPS-2020-01: The Montreal Heart Institute is behind one of two Canadian trials involving colchicine, a medication normally used to treat gout. This trial is partially sponsored by the Bill and Melinda Gates Foundation and is expected to be completed by December.



CONCOR-KIDS: Some pediatric COVID-19 patients in Alberta hospitals are being given this treatment, which uses frozen plasma from recovered patients.



CONTROL-COVID-FAVIPIRAVIR-1: Nova Scotia-based Appili Therapeutics is behind this trial of favipiravir, an antiviral drug most commonly used in Japan.



CORIPREV-1: Lopinavir/ritonavir was approved for treatment of HIV/AIDS infections in 2000, and is now being tested by Unity Health Toronto to see how it affects COVID-19.



COVACTA: Drugmaker Hoffmann-La Roche is testing Actemra, a relatively new arthritis medication, to see how patients with severe pneumonia related to COVID-19respond to it.



COVID-CTP-01: This is another trial involving nitric oxide, this one being carried out in Quebec by Vancouver-based R&D firm SaNOtize.



GRAAL-2020-01: A team from Hamilton Health Sciences is behind a trial thatuses plasma from recovered patients to treat hospitalized adults who have acute cases of COVID-19.



GS-US-540-5821: Another trial investigating antiviral drug remdesivir, this one is being conducted by pharmaceutical company Gilead.



HEROS-1: Hydroxychloroquine is being given to front-line health-care workers for this trial run by the University Health Network in Toronto.



IC.8: The only ongoing Canadian trial to involve a potential vaccine, this tests involves recruiting patients at higher risk of severe complications and giving them IMM-101, a bacteria designed to boost their immune system and keep COVID-19 at bay.



JF-4-2020: The Toronto-based University Health Network is taking part in this trial involving peginterferon-lambda, a part of the human antiviral immune response that proponents believe may have a lower risk of serious side effects than other potential COVID-19 treatments.



LAU-20-01: Fenretinide, which has been found to be effective in fighting some cancer cells, is being tested against COVID-19 in this trial run by Laurent Pharmaceuticals.



LOVIT-COVID: Researchers at the Sherbrooke University Hospital are examining whether high doses of vitamin C can lessen organ dysfunction in hospitalized patients.



MK-4482: Some hospitalized adults with COVID-19 are taking part in this trial, which involves an experimental influenza drug known as MK-4482.



MP-31-2019-2945: COVID-19 patients in intensive care are eligible for this Sherbrooke University Hospital trial examining how high doses of vitamin C affect organ dysfunction.



NCT04405102: A multiple sclerosis-fighting drug known as ozanimod is being given to COVID-19 patients who require oxygen in this Quebec-based trial.



OZM-113: The University of Manitoba is behind this trial, which gives therapeutic doses of blood thinners to participating hospitalized COVID-19 patients.



PHRI.ACT.COVID19: The other Canadian trial to use gout-fighting drug colchicine, this one is being carried out by Hamilton Health Sciences.



PREP2020: Another trial run by researchers from the University of Manitoba, this one involves hydroxychloroquine.



PROTOCOL 214094: COVID-19 patients with severe pulmonary symptoms may be eligible for this trial from pharmaceutical company GlaxoSmithKline, which uses an antibody known as Otilimab.



RAPID COVID COAG: This Toronto-based trial involves the use of blood thinners as a COVID-19 therapy.



REMAP-CAP: This trial involving intensive care patients tracks the effectiveness of several therapies being studied in other entries on this list, including lopinavir/ritonavir, blood thinners and frozen plasma.



SAIL-004: Baricitinib, an arthritis drug, is being tested in hospitalized COVID-19 patients in a trial run by Dr. Lisa Barrett of Dalhousie University.



SAR153191: Another drug normally used to treat arthritis, sarilumab is being tested on some hospitalized COVID-19 patients by pharmaceutical company Sanofi.



U-DEPLOY: This is the second of two Canadian trials involving anti-myelofibrosis treatment ruxolitinib. Researchers in Toronto are monitoring how many COVID-19 patients' symptoms worsen after they are given the drug.



VASCEPA-COVID-19-CARDIOLINK-9: Icosapent, a drug primarily used to help prevent heart issues and strokes, is the focus of this trial.

[Gaon]

Five serious COVID patients recover after experimental Israeli treatment



Enlivex Therapeutics says it administered its Allocetra therapy to severe and critical cases in Jerusalem hospital; all recovered completely, tested negative for coronavirus



The three subjects in severe condition were released from the hospital 5.5 days after receiving the treatment, and the two patients in critical condition were released after 8.5 days. They all tested negative for the coronavirus when they were released, the company said.



Allocetra treats the over-response of the immune system and inflammatory response that is sometimes seen in COVID-19 patients, called a cytokine storm. The phenomenon can cause severe immune system attacks on the body's own organs, causing organ failure and sometimes death.



Cytokine storms are difficult to treat because they are complex responses involving multiple biological systems reacting, and interacting, at the same time. Cytokines are proteins used in cell signaling that summon immune cells during an immune response.



Allocetra uses the body's own regulation mechanisms to tamp down the storm, without hampering the immune system, the company said. The treatment infuses billions of early apoptotic cells, or dying cells, into the bloodstream. Macrophages and dendritic cells, the body's first responders, feed on these apoptotic cells, releasing fewer cytokine alert signals and calming the storm.



The company previously demonstrated the drug's safety in treating a small group of sepsis patients, and now plans to launch Phase II clinical trials for coronavirus patients in severe or critical condition.

https://www.timesofisrael.com/five-serious-covid-patients-recover-after-experimental-israeli-treatment/">https://www.timesofisrael.com/five-seri ... treatment/">https://www.timesofisrael.com/five-serious-covid-patients-recover-after-experimental-israeli-treatment/

[cc]

That's one to pay attention to

[Anonymous]

Five serious COVID patients recover after experimental Israeli treatment



Enlivex Therapeutics says it administered its Allocetra therapy to severe and critical cases in Jerusalem hospital; all recovered completely, tested negative for coronavirus



The three subjects in severe condition were released from the hospital 5.5 days after receiving the treatment, and the two patients in critical condition were released after 8.5 days. They all tested negative for the coronavirus when they were released, the company said.



Allocetra treats the over-response of the immune system and inflammatory response that is sometimes seen in COVID-19 patients, called a cytokine storm. The phenomenon can cause severe immune system attacks on the body's own organs, causing organ failure and sometimes death.



Cytokine storms are difficult to treat because they are complex responses involving multiple biological systems reacting, and interacting, at the same time. Cytokines are proteins used in cell signaling that summon immune cells during an immune response.



Allocetra uses the body's own regulation mechanisms to tamp down the storm, without hampering the immune system, the company said. The treatment infuses billions of early apoptotic cells, or dying cells, into the bloodstream. Macrophages and dendritic cells, the body's first responders, feed on these apoptotic cells, releasing fewer cytokine alert signals and calming the storm.



The company previously demonstrated the drug's safety in treating a small group of sepsis patients, and now plans to launch Phase II clinical trials for coronavirus patients in severe or critical condition.

https://www.timesofisrael.com/five-serious-covid-patients-recover-after-experimental-israeli-treatment/">https://www.timesofisrael.com/five-seri ... treatment/">https://www.timesofisrael.com/five-serious-covid-patients-recover-after-experimental-israeli-treatment/

Good information Gaon.

 

[Anonymous]

US to Pay Eli Lilly $375 Million for 300,000 Vials of Experimental COVID-19 Antibody Drug



The U.S. government will pay Eli Lilly $375 million to secure an initial supply of 300,000 vials of bamlanivimab, the pharma company's experimental COVID-19 drug pending emergency approval by the Food and Drug Administration (FDA).



Eli Lilly on Wednesday announced the deal, adding that it expects to manufacture 1 million doses of bamlanivimab by the end of year, with 100,000 doses ready to ship for use around the world soon after authorization.



It will be used in antibody treatment for "high-risk" COVID-19 patients with mild-to-moderate symptoms, the drugmaker said. If the FDA grants it an Emergency Use Authorization (EUA), the patients will not have to pay for the medicine.



"The initial agreement is for delivery over the two months following an EUA and also provides the option for the U.S. government to purchase up to an additional 650,000 vials through June 30, 2021," the company's statement read.



In September, Eli Lilly reported that the bamlanivimab treatment appeared to reduce the risk that patients would need hospitalization or seek emergency care and help lower CCP virus levels in those with mild or moderate symptoms.



Earlier this week, however, researchers said bamlanivimab was "unlikely" to help patients already hospitalized with COVID-19 recover from their advanced stage, and recommended not to resume study of the drug in that setting.



Lilly is the third antibody drug developer to secure a manufacturing or supply agreement with the Trump administration. In July, the federal government agreed to pay Regeneron $450 million to claim up to 300,000 doses of the New York-based biotech company's experimental COVID-19 antibody drug. Earlier this month, just days after President Donald Trump was treated for COVID-19, the federal government awarded $486 million to British drugmaker AstraZeneca, which is expected to deliver up to 100,000 doses of its antibody drug to the United States by the end of the year.

https://www.theepochtimes.com/us-to-pay-eli-lilly-375-million-for-300000-vials-of-experimental-covid-19-antibody-drug_3556346.html?utm_source=morningbriefnoe&utm_medium=email&utm_campaign=mb-2020-10-29">https://www.theepochtimes.com/us-to-pay ... 2020-10-29">https://www.theepochtimes.com/us-to-pay-eli-lilly-375-million-for-300000-vials-of-experimental-covid-19-antibody-drug_3556346.html?utm_source=morningbriefnoe&utm_medium=email&utm_campaign=mb-2020-10-29

[Anonymous]

US to Pay Eli Lilly $375 Million for 300,000 Vials of Experimental COVID-19 Antibody Drug



The U.S. government will pay Eli Lilly $375 million to secure an initial supply of 300,000 vials of bamlanivimab, the pharma company's experimental COVID-19 drug pending emergency approval by the Food and Drug Administration (FDA).



Eli Lilly on Wednesday announced the deal, adding that it expects to manufacture 1 million doses of bamlanivimab by the end of year, with 100,000 doses ready to ship for use around the world soon after authorization.



It will be used in antibody treatment for "high-risk" COVID-19 patients with mild-to-moderate symptoms, the drugmaker said. If the FDA grants it an Emergency Use Authorization (EUA), the patients will not have to pay for the medicine.



"The initial agreement is for delivery over the two months following an EUA and also provides the option for the U.S. government to purchase up to an additional 650,000 vials through June 30, 2021," the company's statement read.



In September, Eli Lilly reported that the bamlanivimab treatment appeared to reduce the risk that patients would need hospitalization or seek emergency care and help lower CCP virus levels in those with mild or moderate symptoms.



Earlier this week, however, researchers said bamlanivimab was "unlikely" to help patients already hospitalized with COVID-19 recover from their advanced stage, and recommended not to resume study of the drug in that setting.



Lilly is the third antibody drug developer to secure a manufacturing or supply agreement with the Trump administration. In July, the federal government agreed to pay Regeneron $450 million to claim up to 300,000 doses of the New York-based biotech company's experimental COVID-19 antibody drug. Earlier this month, just days after President Donald Trump was treated for COVID-19, the federal government awarded $486 million to British drugmaker AstraZeneca, which is expected to deliver up to 100,000 doses of its antibody drug to the United States by the end of the year.

https://www.theepochtimes.com/us-to-pay-eli-lilly-375-million-for-300000-vials-of-experimental-covid-19-antibody-drug_3556346.html?utm_source=morningbriefnoe&utm_medium=email&utm_campaign=mb-2020-10-29">https://www.theepochtimes.com/us-to-pay ... 2020-10-29">https://www.theepochtimes.com/us-to-pay-eli-lilly-375-million-for-300000-vials-of-experimental-covid-19-antibody-drug_3556346.html?utm_source=morningbriefnoe&utm_medium=email&utm_campaign=mb-2020-10-29

 

[cc]

Up to date Calcs from my spreadsheet



Certainly cases are increasing everywhere in the world and in most every province .. but morbidity levels are slowly going down



It's a bit hard to know the which inputs to use as there is of course a lag between infection and deaths, so I have set the spreadsheet to calculate using



I use Today's Total Deaths for all 3

1. against  ... 2 weeks ago total cases"

2. against ... 1 week ago total cases"

3. against ..  Today's total deaths" ... for comparison between places and an indication only of where it is going



3 is the one usually  published (lazi) but that makes it appear better than it really is - (especially when cases are rising fast)



Between the 3 one can get a pretty good comparative idea of how many each area (province or country) is losing



I would guess that between near 1 &  between 1 & 2 are closest to the truth



In above order 1, 2 & 3. as of last weekend - #s represent Recorded Deaths per 100 Recorded Cases]



So, using Today's Total Deaths

1. against 2 weeks ago total cases" - 2. against 1 week ago total cases" - 3. against Today's total cases



BC > 2.54   2.32   2.04 (In May was ~6)



Alberta > 1.50   1.38      1.24 (always been lowest along with some southern states )



Ontario > 5.34   4.90      4.51



Quebec > 7.89   7.16      6.61



Seems ON & Quebec learned nothing and are not protecting their elders



I didn't log Canada's or other country's total cases and thus have no way to do #1 & #2 for them  .. so here's currents (in effect, method #3 above):



Canada  4.42  (In May was ~8 a few months ago)



US 2.54

Florida 2.1  



UK 4.76

France 2.81

[cc]

I had started a "last cpl of months only method which results in a bit lower numbers but it's complex to do



Unfortunately all I have going back a considerable period of time  is BC and a few others



If I use the list of daily cases and deaths and set it to take only the last cpl of months it would be more up to current better rates  .. but is rather complex and ones I still cannot know the actual time frame from infection to death



OK, I did it.



Just finished taking last 4 weeks of deaths vs. 4 weeks of cases starting 2 weeks previous and numbers for BC dropped to  between 0.8 & 0.9 deaths / 100 cases  from today and also going back for each week and doing the same for for 4 weeks



It slowly got a bit better  better each week starting 4 weeks back in time to today



prolly realistic to weigh this vs the above post



Above (this post and above post) is a bit intricate and could be confusing, so if anyone needs further explanation, just ask





While I log and estimate death rates for for many countries, provinces and state, of course my main focus BC



It just dawned on me that I may be the only BC regular here .. funny, I had never thought about that before .. seems all have become close and locations and distances  I have not related to .